BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Purchases of Investments
Cash used to buy marketable securities and other investments.
BioAge Labs, Inc.NASDAQ: BIOA
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments grows, but more slowly than its trailing trend
Q1 FY2026 purchases of investments of $80.21M (cash outflow) rose 3.4% year over year, behind the +102.9% change in trailing-twelve-month purchases of investments. Sequentially, it rose 99.0% from the prior quarter.
Context
- Purchases of investments amounted to 1720.4% of revenue in FY2025.
- Purchases of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +102.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (154.75M) USD
- Year-over-year change
- —
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (154.75M) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (100K) | — |
| FY2022 | 2022-12-31 | 0 | — |
Purchases of Investments vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +102.9% is the highest of 6, against a peer median of -42.6%.
- Purchases of investments amounts to 1525.8% of revenue for BIOA, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $233.85M USD | -43.9% | -19.7% | — | |
| LTM Mar 2026 | $189.73M USD | -42.6% | -17.7% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $157.4M USD | +102.9% | — | 1525.8% |
| LTM Mar 2026 | $99.04M USD | — | +25.8% | — | |
| LTM Mar 2026 | $19.12M USD | -40.7% | — | 45.7% | |
| LTM Mar 2026 | CA$126.32K CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | CA$0 CAD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -42.6% | -17.7% | 0.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.